Study by Columbia University Medical Center Found That Bone Marrow Disease Drug Ruxolitinib Can Restore Hair Growth In Alopecia Patients
The findings, published in the respected medical journal Nature Medicine, found that the bone marrow disease drug ruxolitinib promotes hair growth in people with alopecia who have severe hair loss.
The study commenced four years ago and included more than 1,000 patients with alopecia. They studied the cause of hair loss in alopecia patients and found that in the disease, hair follicles send a signal to immune cells which causes them to attack the hair follicles.
The study then continued further research into both mice and patients with the disease and discovered different pathways that immune T-cells attack the hair follicles. Researchers found that some of these pathways are targeted by JAK inhibitor drugs. Two types of JAK inhibitors, which have already been authorised by the FDA, were tested on mice with alopecia and hair loss. These were ruxolitinib and tofacitinib.
The scientists said that both of these drugs completely restored the re-growth of hair in the mice within a period of 12 weeks.
Ruxolitinib clinical trials have also taken place in humans with alopecia related hair loss, and it was found that hair regrowth was fully restored 4-5 months,on average, after the start of treatment. The scalps of these volunteers were also tested, and the researchers found no trace of hair follicle attacking T-cells.
Read more about it here: Baldness cured with bone marrow disease drug in alopecia areata patients